Clinical Proteomics and Bioinformatics: Exploring Drug Resistant Tuberculosis

Abstract

Tuberculosis (TB) is a major public health problem across the globe. As per WHO, 10.4 million new TB cases and 1.8 million deaths occur annually [1]. In developing countries, TB burden among the healthcare workers is a serious issue [2] and spreading of drug-resistant Mycobacterium tuberculosis strains further worsened the situation which leads to the emergence of multidrug-resistant tuberculosis (MDR-TB), extensively drug-resistant tuberculosis (XDRTB) and totally drug-resistant tuberculosis (TDR-TB). Use of effective diagnostics and therapeutics strategies are the only valid options to combat the situation of global antibiotic resistance [3,4]. Researchers have paid attention in this direction and trying to develop alternative strategies against global antibiotic resistance. Repurposing of the drugs against the antibiotics resistant M. tuberculosis infection has been considered as an effective strategy and might be shown the positive outcomes in the treatment of MDR-TB, XDR-TB and TDR-TB [4]. Still, our current therapeutic strategies are unable to give complete protection against antibiotics resistant TB infections. Therefore, an urgent need is required for developing the possible diagnostics and therapeutic strategies against the antibiotics resistance.